1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Suraputide Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 1 mg (0.5 mL) / pen
  • 1.3.3 3 mg (0.5 mL) / pen
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Suraputide Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combination of Supaglutide and Metformin
  • 1.4.3 Combination of Supaglutide and DPP-4 inhibitors
• 1.5 Market Analysis by Sales Channel
  • 1.5.1 Overview: Global Suraputide Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospital
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Suraputide Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Type 2 Diabetes Mellitus
  • 1.6.3 Obesity
  • 1.6.4 Metabolic Syndrome
  • 1.6.5 Others
• 1.7 Global Suraputide Market Size & Forecast
  • 1.7.1 Global Suraputide Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Suraputide Sales Quantity (2021-2032)
  • 1.7.3 Global Suraputide Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Guangzhou InnoGen Pharmaceuticals
  • 2.1.1 Guangzhou InnoGen Pharmaceuticals Details
  • 2.1.2 Guangzhou InnoGen Pharmaceuticals Major Business
  • 2.1.3 Guangzhou InnoGen Pharmaceuticals Suraputide Product and Services
  • 2.1.4 Guangzhou InnoGen Pharmaceuticals Suraputide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Guangzhou InnoGen Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Suraputide by Manufacturer

• 3.1 Global Suraputide Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Suraputide Revenue by Manufacturer (2021-2026)
• 3.3 Global Suraputide Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Suraputide by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Suraputide Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Suraputide Manufacturer Market Share in 2025
• 3.5 Suraputide Market: Overall Company Footprint Analysis
  • 3.5.1 Suraputide Market: Region Footprint
  • 3.5.2 Suraputide Market: Company Product Type Footprint
  • 3.5.3 Suraputide Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Suraputide Market Size by Region
  • 4.1.1 Global Suraputide Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Suraputide Consumption Value by Region (2021-2032)
  • 4.1.3 Global Suraputide Average Price by Region (2021-2032)
• 4.2 North America Suraputide Consumption Value (2021-2032)
• 4.3 Europe Suraputide Consumption Value (2021-2032)
• 4.4 Asia-Pacific Suraputide Consumption Value (2021-2032)
• 4.5 South America Suraputide Consumption Value (2021-2032)
• 4.6 Middle East & Africa Suraputide Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Suraputide Sales Quantity by Type (2021-2032)
• 5.2 Global Suraputide Consumption Value by Type (2021-2032)
• 5.3 Global Suraputide Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Suraputide Sales Quantity by Application (2021-2032)
• 6.2 Global Suraputide Consumption Value by Application (2021-2032)
• 6.3 Global Suraputide Average Price by Application (2021-2032)

7 North America

• 7.1 North America Suraputide Sales Quantity by Type (2021-2032)
• 7.2 North America Suraputide Sales Quantity by Application (2021-2032)
• 7.3 North America Suraputide Market Size by Country
  • 7.3.1 North America Suraputide Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Suraputide Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Suraputide Sales Quantity by Type (2021-2032)
• 8.2 Europe Suraputide Sales Quantity by Application (2021-2032)
• 8.3 Europe Suraputide Market Size by Country
  • 8.3.1 Europe Suraputide Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Suraputide Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Suraputide Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Suraputide Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Suraputide Market Size by Region
  • 9.3.1 Asia-Pacific Suraputide Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Suraputide Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Suraputide Sales Quantity by Type (2021-2032)
• 10.2 South America Suraputide Sales Quantity by Application (2021-2032)
• 10.3 South America Suraputide Market Size by Country
  • 10.3.1 South America Suraputide Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Suraputide Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Suraputide Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Suraputide Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Suraputide Market Size by Country
  • 11.3.1 Middle East & Africa Suraputide Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Suraputide Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Suraputide Market Drivers
• 12.2 Suraputide Market Restraints
• 12.3 Suraputide Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Suraputide and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Suraputide
• 13.3 Suraputide Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Suraputide Typical Distributors
• 14.3 Suraputide Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Suraputide market size was valued at US$ 18.67 million in 2025 and is forecast to a readjusted size of US$ 540 million by 2032 with a CAGR of 16.8% during review period.
Suraputide is an innovative long‑acting GLP‑1 receptor agonist independently developed in China. By activating the GLP‑1 receptor, it promotes insulin secretion and inhibits glucagon release in a glucose‑dependent manner, thereby effectively lowering blood glucose. It also exerts effects of delaying gastric emptying, suppressing appetite, reducing body weight, and providing potential cardiorenal protection. The drug achieves long‑acting activity through Fc fusion protein technology and is administered by subcutaneous injection once weekly. It is mainly indicated for glycemic control in adults with type 2 diabetes mellitus. As the first domestically invented long‑acting GLP‑1 analogue approved in China, it features favorable safety, convenient administration and high compliance, and offers important clinical value for potential expansion into indications such as obesity and metabolic syndrome.In 2025, global Suraputide production reached approximately 300,000 vials.
As the first domestically developed long‑acting GLP‑1 receptor agonist in China, suraputide operates in a rapidly expanding and highly competitive market for metabolic disease drugs. With the convenience of once‑weekly administration, favorable safety profile, and locally tailored pricing advantages, the product has quickly entered the field of type 2 diabetes treatment since its launch. Its inclusion in medical insurance has further boosted both market coverage and patient accessibility. Although the current market is dominated by international pharmaceutical giants, accompanied by intensified competition among similar products and pressure on pricing, suraputide has established distinctive competitiveness in the two core sectors of diabetes and weight management by relying on its differentiated Fc fusion protein technology, as well as local R&D and commercialization strengths. In the long run, with the gradual expansion of indications to include obesity and metabolic syndrome, the advancement of overseas market deployment, and the rising penetration rate and consumption upgrade of GLP‑1 drugs in China, the product is expected to continuously expand its market share in the trillion‑level market and become an important benchmark for domestic innovative drugs in the field of metabolic diseases.
This report is a detailed and comprehensive analysis for global Suraputide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Suraputide market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Suraputide market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Suraputide market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Suraputide market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Suraputide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Suraputide market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guangzhou InnoGen Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Suraputide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1 mg (0.5 mL) / pen
3 mg (0.5 mL) / pen
Market segment by Combination Therapy
Combination of Supaglutide and Metformin
Combination of Supaglutide and DPP-4 inhibitors
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Type 2 Diabetes Mellitus
Obesity
Metabolic Syndrome
Others
Major players covered
Guangzhou InnoGen Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Suraputide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Suraputide, with price, sales quantity, revenue, and global market share of Suraputide from 2021 to 2026.
Chapter 3, the Suraputide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Suraputide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Suraputide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Suraputide.
Chapter 14 and 15, to describe Suraputide sales channel, distributors, customers, research findings and conclusion.